all prices
| price | high | low | % | ||
|---|---|---|---|---|---|
| Dow Jones | 27963 | 27976 | 27689 | 0.99 % | |
| S&P500 | 3145 | 3146 | 3118 | 0.85 % | |
| Nasdaq 100 | 8385 | 8389 | 8311 | 0.89 % | |
| Euro Stoxx 50 | 3691 | 3694 | 3657 | 0.96 % | |
| FTSE 100 | 7240 | 7242 | 7149 | 1.34 % | |
| CAC40 | 5872 | 5877 | 5818 | 0.96 % | |
| DAX | 13160 | 13172 | 13061 | 0.62 % | |
| Hong Kong HSI | 26536 | 26564 | 26291 | 1.18 % | |
| Nikkei 225 | 23543 | 23572 | 23329 | 0.81 % |
Live stock markets prices
- 15 min
- 1H
- 4H
- Daily
| Dow Jones | 27962 | 0.99% |
|---|---|---|
| S&P500 | 3145 | 0.86% |
| Nasdaq 100 | 8385 | 0.89% |
| FTSE 100 | 7240 | 1.34% |
| CAC40 | 5872 | 0.96% |
|---|---|---|
| Nikkei 225 | 23545 | 0.82% |
| Euro Stoxx 50 | 3691 | 0.96% |
| DAX | 13160 | 0.62% |
Latest news
| American medical device specialist joins the board of directors of WATGEN MEDICAL A/S |
| Nexans : Information on share capital and voting rights - November 2019 |
| Domo, Inc. (DOMO), Infosys Limited (INFY) & Pareteum Corporation (TEUM) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Upcoming Deadlines |
| DEADLINE ALERT - Ruhnn Holding Limited (RUHN) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: December 6, 2019 |
| SHAREHOLDER ALERT - Sonim Technologies, Inc. (SONM) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: December 6, 2019 |
| DEADLINE ALERT - The Chemours Company (CC) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: December 9, 2019 |
| Alliance Trust PLC - Net Asset Value |
| Norwegian Finans Holding ASA: Bank Norwegian AS - issuance of senior unsecured bonds |
| Bank Norwegian AS: Bank Norwegian AS - issuance of senior unsecured bonds |
| Form 8.3 - [Allergan plc] |
| Form 8.3 - [ AbbVie Inc.] |
| Middlefield Canadian Income PCC: Net Asset Value(s) |
| Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia |
| Northrim BanCorp, Inc. Declares Quarterly Cash Dividend of $0.33 per Share |
| Prophix Software Recognized as November 2019 Gartner Peer Insights Customers’ Choice for Cloud Financial Planning Analysis Solutions |
| Leading Victim Notification Service Celebrates 25 Years |
| 2nd Watch Earns 2019 Cloud Services Provider of the Year Award |
| Beter Bed Holding announces sale and lease-back of the distribution centers in Hoogeveen and Nieuw-Vennep |
| VILNIAUS BALDAI AB investor's calendar for 2020FY |
| Share Buy-back programme at SP Group A/S |
American medical device specialist joins the board of directors of WATGEN MEDICAL A/S
Company Announcement No. 20
Vejle, December 6th, 2019
American medical device specialist Jonathan Sorger, Vice President - Research, INTUITIVE SURGICAL (NASDAQ: ISRG), joins the board of directors of WATGEN MEDICAL A/S.
Waturu Holding A/S owns 87.5% of WATGEN MEDICAL A/S. The remaining ownership is split between Belair Medical ApS with 10%, owned by co-founder, doctor and professor, Peter Bjerring and by Huidzaken Holding ApS with 2.5%, owned by Jesper Nørregaard, CEO WATGEN MEDICAL A/S.
WATGEN MEDICAL A/S is developing solutions to ensure better treatment of chronic wound care patients. WATGEN MEDICAL A/S also researches in the development of a new type of treatment for patients with inflammatory skin diseases such as childhood eczema.
About the new board profile:
Jonathan Sorger comes with an MBA from John Hopkins University, Ph.D, Biomedical Engineering, JH School of Medicine as well as B.S., Bioengineering from the University of California. Jonathan Sorger has a broad experience in the field of life-science and within medical equipment technology. Jonathan Sorger is a skilled technical specialist with a focus on commercialization. He is an inventor and co-inventor of more than 20 issued or pending patents. He has also achieved impressive results in identifying and addressing significant unmet clinical needs, with innovative technology solutions.Â
âThe impact of a diabetic foot ulcer on the life of a patient can be devastating - causing repeated hospitalizations, surgeries for vascular repair, even amputation. With a lifetime risk of a diabetic patient developing this complication estimated to be up to 15% and the cost to heal an average of $20,000 USD, the opportunity to meaningfully impact patientâs lives and reduce the cost-burden to healthcare systems around the world is significantâ- says Jonathan Sorger.
"It is with great pleasure that I welcome Jonathan and I expect Jonathan to be able to contribute actively with knowledge and networks within wound care, which is a large market in the US - as it is globally" - says CEO Jesper Nørregaard.
Jonathan Sorger becomes the first foreign member of the board of directors of WATGEN MEDICAL A/S, where an expectation was previously announced to the market, based on an LOI with a professional investor, about a PRE-IPO capital increase of 10 MDKK to WATGEN MEDICAL A/S. The LOI agreement also includes the investor participating in an upcoming IPO of WATGEN MEDICAL A/S, where a value estimate of +250 MDKK is expected, based on the market as well as external professional investors.
More information:
CEO Toke Reedtz, tel .: +45 5188 1262, e-mail: toke@waturu.com
CFO Michael Nørgaard, tel .: +45 2720 6214, e-mail: mn@waturu.com
Waturu Holding A/S
Sjællandsgade 32
7100 Vejle
Certified Adviser
Västra Hammen Corporate Finance AB
Per Lönn, tel +46 40 200 255
Jungmansgatan 12 211 11 Malmö Sweden
www.vhcorp.se
Nasdaq First North Growth Market Important links:
The website:
www.waturu.com
Financial reports:
www.waturu.com/documents
Continuous updates from the company:
www.waturu.com/news
www.linkedin.com/company/waturu/
www.facebook.com/WaturuDenmark/
Nexans : Information on share capital and voting rights - November 2019
Information on share capital and voting rights
November 2019
Statement made in accordance with article L. 233-8 II of the French commercial Code and articles 221-1 2 ° f) and 223-16 of the AMF Regulations.
December 6th, 2019
Statement made by:
Nexans S.A.
Registered office : 4 Allée de lâArche - 92400 Courbevoie
RCS Nanterre 393Â 525Â 852
Regulated market of Euronext Paris (Compartment A)
| Date | Total number of shares | Total number of voting rights | |
| Theorical (1) | Exercisable (2) | ||
| Â November 30th, 2019 | Â 43,606,320 Â | Â 43,606,320 | Â 43,449,835 |
- Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulations).
 -  For information, excluding treasury shares stripped of voting rights.
            Â
Provision of Nexans articles of association requiring shareholders to declare the crossing of threshold other than the legal thresholds: yes.
Extract of article 7 of Nexans articles of association: âFully paid up shares may be registered or bearer at the option of the shareholder. In addition to the legal obligation to inform the company when certain fractions of the share capital are held, any natural or legal person and/or shareholder owning a number of shares in the company equal to or greater than 2 % of the share capital or voting rights must notify the company of the total number of shares held, within a period of fifteen days from the time the threshold is crossed, by registered letter with acknowledgement of receipt. A further notification must be sent, in accordance with the conditions hereof, each time that a multiple of 2 % is reached.â
Attachment
Domo, Inc. (DOMO), Infosys Limited (INFY) & Pareteum Corporation (TEUM) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Upcoming Deadlines
NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.Â
Domo, Inc. (NASDAQ: DOMO)
Class Period: shareholders who purchased Domo securities (1) from June 26, 2018 through September 5, 2019, inclusive (the âClass Periodâ); or (2) pursuant and/or traceable to the Companyâs registration statement and related prospectus issued in connection with the Companyâs initial public offering (âIPOâ or the âOfferingâ) commenced on or about June 29, 2018.
Deadline: December 16, 2019
For more info: www.bgandg.com/domo
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Domo was experiencing weakness in its enterprise and international businesses; (2) Domoâs billings growth had dramatically slowed; (3) all of the foregoing was reasonably likely to have a material negative impact on the Companyâs financial results; and (4) as a result, Domoâs public statements were materially false and misleading at all relevant times.Â
Infosys Limited (NYSE: INFY)
Class Period: July 7, 2018 - October 20, 2019
Deadline: December 23, 2019
For more info: www.bgandg.com/infy
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company improperly recognized revenues to inflate short-term profits; (2) the Companyâs CEO, Salil Parekh, bypassed reviews and approvals for large deals to avoid accounting scrutiny; (3) management pressured the Companyâs finance team to hide information from auditors and the Companyâs Board of Directors; and (4) as a result, defendantsâ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.Â
Pareteum Corporation (NASDAQ: TEUM)
Losses: Shareholders who have lost over $100K
Class Period: December 14, 2017 - October 21, 2019
Deadline: December 23, 2019
For more info: www.bgandg.com/teum
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Pareteum improperly and inaccurately recognized revenue for certain customer transactions; (2) Pareteum's financial statements for the fiscal year ending December 31, 2018 and quarters of ending March 31, 2019 and June 30, 2019were false and could not be relied on; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.Â
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
DEADLINE ALERT - Ruhnn Holding Limited (RUHN) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: December 6, 2019
NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ruhnn Holding LimitedÂ
 (âRuhnnâ or the âCompanyâ) (NASDAQ: RUHN) and certain of its officers, on behalf of shareholders who purchased Ruhnn securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with Ruhnn's April 3, 2019 initial public stock offering (the "IPO" or the "Offering"). Such investors are encouraged to join this case by visiting the firmâs site: www.bgandg.com/ruhn.  Â
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that the Registration Statement was false and/or misleading statements and/or failed to disclose that: (1) at the time of the IPO, the number of Ruhnn's online stores had declined by nearly 40%; (2) at the time of the IPO, the number of Ruhnn's full-service Key Opinion Leaders had declined by nearly 44%; (3) as a result, the Company's net revenues derived from its full-service segment had declined by 46% on a sequential basis; and (3) as a result, defendants' statements about Ruhnn's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.Â
If you wish to review a copy of the Complaint you can visit the firmâs site: www.bgandg.com/ruhn or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Ruhnn you have until December 6, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firmâs expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
SHAREHOLDER ALERT - Sonim Technologies, Inc. (SONM) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: December 6, 2019
NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Sonim Technologies, Inc. (âSonimâ or the âCompanyâ) (NASDAQ: SONM) and certain of its officers, on behalf of shareholders who purchased Sonim securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with Sonim's May 2019 initial public stock offering (the "IPO" or the "Offering"). Such investors are encouraged to join this case by visiting the firmâs site: www.bgandg.com/sonm.Â
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that the Registration Statement was false and/or misleading statements and/or failed to disclose that: (1) the Company's XP8 was experiencing material software challenges; (2) these software issues adversely affected how the device's Qualcomm chipset, which supported Band 14 access, connected to AT&T's carrier network configuration; (3) the Company's XP5 and XP3 devices were experiencing material software defects that adversely affected their optimization with certain accessories; (4) as a result, the Company was reasonably likely to delay the launch of new products; (5) as a result of the foregoing, the Company's financial results would be materially and adversely impacted; and (6) as a result, defendants' statements about Sonim's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.Â
On September 10, 2019, Sonim issued updated financial guidance for fiscal year 2019, advising investors that â[n]et revenues are expected to be flat or slightly below 2018 net revenues of $135.7 million reported in fiscal 2018,â âGAAP net loss . . . is expected to be up to $15 million,â and â[a]djusted EBITDA . . . is expected to be a loss of up to $5 million.â Sonim cited âchanges in U.S. wireless carrier forecasts for the launch of Sonimâs new products as well as launch delays due to software issues related to these new introductionsâ as factors contributing to the Companyâs revised financial outlook.  On this news, Sonimâs stock price fell $3.30 per share, or 46.74%, to close at $3.76 per share on September 10, 2019.
If you wish to review a copy of the Complaint you can visit the firmâs site: www.bgandg.com/sonm or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Sonim you have until December 6, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firmâs expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
DEADLINE ALERT - The Chemours Company (CC) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: December 9, 2019
NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against The Chemours Company (âChemoursâ or the âCompanyâ) (NYSE: CC) and certain of its officers, on behalf of shareholders who purchased Chemours securities between February 16, 2017 and August 1, 2019 (the âClass Periodâ). Such investors are encouraged to join this case by visiting the firmâs site: www.bgandg.com/cc.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The Complaint alleges that, throughout the Class Period, Defendants misled investors by representing that Chemours had appropriately accounted and accrued reserves for its environmental liabilities, that the possibility of costs exceeding accrued amounts was "remote," and that, in any event, additional costs would not be material. The complaint continues to allege that Chemours also assured investors that its "policies, standards and procedures are properly designed to prevent unreasonable risk of harm to people and the environment," and that its "handling, manufacture, use and disposal of hazardous substances are in accordance with applicable environmental laws and regulations." Consequently, the Company's shares traded at artificially inflated prices throughout the Class Period.
If you wish to review a copy of the Complaint you can visit the firmâs site: www.bgandg.com/cc or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Chemours you have until December 9, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firmâs expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
Alliance Trust PLC - Net Asset Value
ALLIANCE TRUST PLC
                                 Â
At the close of business Thursday 5 December 2019:
The Companyâs NAV per ordinary share, valued on a bid price basis with Debt at Par, was
-Â Â Â Â Â Â excluding income, 852.8p
-Â Â Â Â Â Â including income, 855.9p
 Â
The Companyâs NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was
-Â Â Â Â Â Â excluding income, 841.6p
-Â Â Â Â Â Â including income, 844.7p
For further information, please contact: -
| Â |
| Alliance Trust PLC |
| Tel. +44 (0)1382 938320 |
Notes
- Net Asset Values are calculated in accordance with published accounting policies and AIC guidelines.
- The fair value of the Companyâs fixed loan notes is calculated by reference to a benchmark gilt.
- The dividend of 3.49p, due to be paid on 31 December 2019, has been deducted from each of the âincluding incomeâ figures cited above as from 5 December 2019, being the date upon which the Companyâs shares went ex-dividend.
Norwegian Finans Holding ASA: Bank Norwegian AS - issuance of senior unsecured bonds
Bank Norwegian AS refers to the announcements on 5 December 2019 regarding issuance of NOK and SEK bonds.
Based on yesterdayâs transaction, we have today received a reverse inquiry, and Bank Norwegian has today issued a new SEK 600 million bond issue with a 4-year tenor. The new bond carries a coupon equal to 3 months STIBOR + 2.00% p.a, and the settlement date is 12 December 2019.
Â
DNB Markets and Nordea Bank Abp acted as joint lead managers.
Â
Fornebu, 6 December 2019
Contact persons:
CFO PÃ¥l Svenkerud; phone +47 93403904
Head of treasury Mats Benserud; phone +47 95891539
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Bank Norwegian AS: Bank Norwegian AS - issuance of senior unsecured bonds
Bank Norwegian AS refers to the announcements on 5 December 2019 regarding issuance of NOK and SEK bonds.
Based on yesterdayâs transaction, we have today received a reverse inquiry, and Bank Norwegian has today issued a new SEK 600 million bond issue with a 4-year tenor. The new bond carries a coupon equal to 3 months STIBOR + 2.00% p.a, and the settlement date is 12 December 2019.
DNB Markets and Nordea Bank Abp acted as joint lead managers.
Fornebu, 6 December 2019
Contact persons:
CFO PÃ¥l Svenkerud; phone +47 93403904
Head of treasury Mats Benserud; phone +47 95891539
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Form 8.3 - [Allergan plc]
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | State Street Global Advisors & Affiliates |
| Company dealt in | Allergan plc |
| Class of relevant security to which the dealings being disclosed relate (Note 2) | US$0.0001 ordinary shares |
| Date of dealing | 05th December 2019 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | |||
| Number | (%) | Number | (%) | |
| (1) Relevant securities | 15,125,920 | 4.60571% | ||
| (2) Derivatives (other than options) | N/A | |||
| (3) Options and agreements to purchase/sell | N/A | |||
| Total | 15,125,920 | 4.60571% | ||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
| Class of relevant security: | Long | Short | ||
| Number | (%) | Number | (%) | |
| (1) Relevant securities | N/A | |||
| (2) Derivatives (other than options) | N/A | |||
| (3) Options and agreements to purchase/sell | N/A | |||
| Total | N/A | |||
3. DEALINGS (Note 4)
(a) Purchases and sales
| Purchase/sale | Number of relevant securities | Price per unit (Note 5) |
| Purchase | 500 | 186.08 |
| Purchase | 300 | 186.08 |
| Purchase | 3,940 | 186.08 |
| Purchase | 30 | 186.08 |
| Sale | 1,633 | 186.08 |
| Sale | 300 | 186.08 |
| Sale | 9,324 | 186.08 |
| Sale | 2,024 | 186.08 |
| Sale | 1,366 | 186.64 |
(b) Derivatives transactions (other than options transactions)
| Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
| N/A |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
| Product name, e.g. call option | Writing, selling, purchasing varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
| N/A |
(ii) Exercising
| Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
| N/A |
(d) Other dealings (including transactions in respect of new securities) (Note 4)
| Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
| N/A |
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
| Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. |
| N/A |
| Is a Supplemental Form 8 attached? (Note 9) | NO |
| Date of disclosure | 06th December 2019 |
| Contact name | Lionel Colaco |
| Telephone number | 020 33956098 |
| If a connected EFM, name of offeree/offeror with which connected | N/A |
| If a connected EFM, state nature of connection (Note 10) | N/A |
Form 8.3 - [ AbbVie Inc.]
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | State Street Global Advisors & Affiliates |
| Company dealt in | AbbVie Inc. |
| Class of relevant security to which the dealings being disclosed relate (Note 2) | US$0.01 common stock |
| Date of dealing | 05th December 2019 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | |||
| Number | (%) | Number | (%) | |
| (1) Relevant securities | 68,358,319 | 4.62236% | ||
| (2) Derivatives (other than options) | N/A | |||
| (3) Options and agreements to purchase/sell | N/A | |||
| Total | 68,358,319 | 4.62236% | ||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
| Class of relevant security: | Long | Short | ||
| Number | (%) | Number | (%) | |
| (1) Relevant securities | N/A | |||
| (2) Derivatives (other than options) | N/A | |||
| (3) Options and agreements to purchase/sell | N/A | |||
| Total | N/A | |||
3. DEALINGS (Note 4)
(a) Purchases and sales
| Purchase/sale | Number of relevant securities | Price per unit (Note 5) |
| Purchase | 1,424 | 86.72 |
| Purchase | 17,740 | 86.72 |
| Purchase | 135 | 86.72 |
| Sale | 7,223 | 86.72 |
| Sale | 1,100 | 86.72 |
| Sale | 42,042 | 86.72 |
| Sale | 1,443 | 86.72 |
(b) Derivatives transactions (other than options transactions)
| Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
| N/A |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
| Product name, e.g. call option | Writing, selling, purchasing varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
| N/A |
(ii) Exercising
| Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
| N/A |
(d) Other dealings (including transactions in respect of new securities) (Note 4)
| Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
| N/A |
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
| Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. |
| N/A |
| Is a Supplemental Form 8 attached? (Note 9) | NO |
| Date of disclosure | 06th December 2019 |
| Contact name | Lionel Colaco |
| Telephone number | 020 33956098 |
| If a connected EFM, name of offeree/offeror with which connected | N/A |
| If a connected EFM, state nature of connection (Note 10) | N/A |
Middlefield Canadian Income PCC: Net Asset Value(s)
Middlefield Canadian Income PCC Net Asset Value
Middlefield Canadian Income PCC
Middlefield Canadian Income - GBP PC
(a protected cell company incorporated in Jersey with registration number 93546)
Legal Entity Identifier: 2138007ENW3JEJXC8658
Net Asset Value
As at the close of business on 05 December 2019 the estimated unaudited Net Asset Value per share was 114.42 pence (including accrued income).
Investments in the Companyâs portfolio have been valued on a closing price basis.
Enquiries:
JTC Fund Solutions (Jersey) Limited
01534 700 000
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia
SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to APVO436, a bispecific antibody candidate intended for the treatment of acute myelogenous leukemia (AML). APVO436 is currently being evaluated in a Phase 1/1b clinical trial in patients with AML and myelodysplastic syndrome (MDS).
The U.S. Orphan Drug Act is intended to encourage companies to develop safe and effective therapies for the treatment of rare diseases and conditions, specifically those expected to affect fewer than 200,000 people in the United States. Orphan drug designation provides important benefits to companies such as eligibility for a special seven-year period of market exclusivity upon approval, potential tax credits for research, potential grant funding for research and development, reduced filing fees for marketing applications, and assistance with clinical trial protocol review.
âWe are making steady progress in our ongoing Phase 1/1b clinical trial of APVO436 and are pleased to have been granted orphan drug designation for APVO436, as this designation affords important benefits as we continue to advance APVO436 through clinical development,â said Marvin L. White, President and Chief Executive Officer of Aptevo. âWe look forward to providing future updates on the APVO436 clinical development program as additional data from the Phase 1/1b clinical trial becomes available.â
About APVO436
APVO436 is an optimized bispecific antibody candidate designed to simultaneously target CD123 and CD3 and redirect T-cell cytotoxicity to the tumor. It is currently being evaluated in a Phase 1/1b open-label, dose-escalation study evaluating safety and pharmacokinetics. APVO436 was built on Aptevoâs proprietary ADAPTIR⢠protein therapeutic platform. Focused on generating novel, targeted bispecific antibody-based immunotherapies for cancer the ADAPTIR platform offers key advantages over other bispecific formats, derived in part from the flexible and modular nature of the ADAPTIR structure. These advantages include: (i) achieving potent biological activity and extended half-life while retaining desirable manufacturing characteristics; (ii) ability to achieve target-dependent induction of redirected T-cell cytotoxicity (RTCC) at lower concentrations than other bispecific antibody formats; and (iii) flexibility to build ADAPTIR candidates with diverse mechanisms of action, including RTCC and T-cell co-stimulation.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer. For more information, please visit www.aptevotherapeutics.com
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding potential milestone payments, Aptevoâs outlook, financial performance or financial condition, Aptevoâs technology and related pipeline, collaboration and partnership opportunities, commercial portfolio, milestones, and any other statements containing the words âbelieves,â âexpects,â âanticipates,â âintends,â âplans,â âforecasts,â âestimates,â âwillâ and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevoâs current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevoâs expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause Aptevoâs actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevoâs business or prospects; adverse developments in research and development; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in Aptevoâs filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as filed on March 18, 2019 and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevoâs expectations in any forward-looking statement.
Source:
Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
206-859-6628
JurchisonS@apvo.com
Northrim BanCorp, Inc. Declares Quarterly Cash Dividend of $0.33 per Share
ANCHORAGE, Alaska, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Northrim BanCorp, Inc. (NASDAQ: NRIM) today announced that the Board of Directors declared a regular quarterly cash dividend of $0.33 per share. The dividend will be payable on December 27, 2019, to shareholders of record at the close of business on December 19, 2019.
âWe are committed to providing returns to our shareholders through earnings growth, building equity, and paying reliable dividends,â said Joe Schierhorn, President and CEO. At the stock price of $36.67 per share at the close of the market on December 5, 2019, the current dividend equates to a yield of 3.60% on an annualized basis.
On October 28, 2019, Northrim reported earnings of $7.5 million, or $1.11 per diluted share, for the third quarter of 2019. Return on average assets was 1.90%, return on average equity was 14.45%, and net interest margin was 4.60% for the third quarter of 2019.
About Northrim BanCorp
Northrim BanCorp, Inc. is the parent company of Northrim Bank, an Alaska-based community bank with 16 branches in Anchorage, the Matanuska Valley, Juneau, Fairbanks, Ketchikan, Sitka and Soldotna, serving 90% of Alaskaâs population; and an asset based lending division in Washington; and a wholly-owned mortgage brokerage company, Residential Mortgage Holding Company, LLC. The Bank differentiates itself with its detailed knowledge of Alaskaâs economy and its âCustomer First Serviceâ philosophy. Pacific Wealth Advisors, LLC is an affiliated company of Northrim BanCorp.
| Contact: | Joe Schierhorn, President, CEO, and COO |
| Â | (907) 261-3308 |
| Â | Jed Ballard, Chief Financial Officer |
| Â | (907) 261-3539 |
Prophix Software Recognized as November 2019 Gartner Peer Insights Customers’ Choice for Cloud Financial Planning Analysis Solutions
The Gartner Peer Insights Customersâ Choice Distinction is based on feedback and ratings from end-user professionals who have experience purchasing, implementing, and/or using a product or service.
MISSISSAUGA, Ontario, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Prophix Software, a leading provider of FP&A solutions, is excited to share that they were named a November 2019 Gartner Peer Insights Customersâ Choice for Cloud Financial Planning Analysis Solutions.
The 2019 Gartner Peer Insights Customersâ Choice Distinction is based on feedback and ratings from end-user professionals who have experience purchasing, implementing, and/or using the product or service.
Gartner defines Cloud Financial Planning Analysis as solutions that support the office of finance's budgeting, planning and forecasting efforts. Many also supplement the office's budgeting and planning process support with modeling, collaboration analytics, and performance-reporting capabilities, to increase its ability to manage performance by linking corporate strategy and execution.
Gartner further explains that âthe FP&A market is accelerating its shift from mature-on premises offerings to cloud solutions. New solutions built or significantly rearchitected as cloud services are typically easier to use and maintain than the previous generation of on-premises offerings. The vast majority of new FP&A sales are cloud-based. On-premises options still exist, but all vendors have greatly de-emphasized them or eliminated them entirely from their sales process. All vendors in the Cloud Financial Planning Analysis market sell and support cloud-based FP&A solutions.â
Prophix feels that its Customer Choice distinction is based on exceptional customer satisfaction, strong product capabilities, and robust service and support. Customers rated Prophix Software with a 4.5 out of 5 for the Cloud Financial Planning and Analysis Solutions market based on 92 ratings (Gartner Peer Insights, as of November 18, 2019).
A recent reviewer in the manufacturing industry said, âProphix is a great tool, it provides great value for the price. It is such a great solution that I brought it with me when I changed organizations. The tool is controlled by the finance team, we need very little IT support, and in an organization with multiple priorities, it is critical to have control over our financial reporting and budgeting tool.â
âWe donât just sell software, we are invested in the success of our customers,â said Alok Ajmera, President & COO, Prophix Software. âWe believe being selected as a Gartner Peer Insights Customersâ Choice demonstrates our commitment to our users.â
To learn more about how customers are using Prophix for FP&A, visit our website.
About Peer Insights
Peer Insights is an online platform of ratings and reviews of IT software and services that are written and read by IT professionals and technology decision-makers. The goal is to help IT leaders make more insightful purchase decisions and help technology providers improve their products by receiving objective, unbiased feedback from their customers. Gartner Peer Insights includes more than 215,000 verified reviews in more than 340 markets. For more information, please visit www.gartner.com/reviews/home.
Gartner Peer Insights Customersâ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates.
About Prophix Software
Your business is evolving. Your systems should evolve too. Achieve your goals more successfully with Prophixâs innovative Corporate Performance Management (CPM) software. Improve profitability and minimize risk when you automate repetitive tasks and focus on what matters. Budget, plan, consolidate and report automatically. Whether in the cloud or on-premise, Prophix supports your future with a platform that flexes to suit your strategic realities, today and tomorrow.
Contact
Rachel Douglas
Senior Manager, Marketing Communications & Brand
Prophix Software Inc
rdouglas@Prophix.com
905-279-8711 x502
Leading Victim Notification Service Celebrates 25 Years
Louisville, KY, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Appriss Inc., the developers of VINEâor Victim Information and Notification Everydayâhas announced that the service is today marking 25 years providing automated notifications to crime victims and survivors across the United States.
VINE was developed by current Appriss CEO, Mike Davis, and his then-business partner, Yung Nguyen, in response to the tragic murder of a young Louisville woman named Mary Byron. Mary had been brutally raped and assaulted by a former partner, who was subsequently arrested and incarcerated for these acts. Two weeks later, unbeknownst to Mary and her family, her assaulter posted bond and was freed. On the evening of December 6, 1993, Maryâs 21st birthday, he stalked and killed her as she sat warming her car after leaving work at a local mall.
VINE was launched in Jefferson County, KY on December 6, 1994âexactly one year after Maryâs murder. Twenty-five years later, VINE has grown to be the number one victim notification network in the nation, empowering millions of victims and concerned citizens with timely and reliable information regarding offender custody status. Delivering over 40 million notifications each year, VINE allows victims and survivors to proactively plan for their safetyâan opportunity Mary did not have. Today, this life-saving service is active in 48 statesâcovering approximately 3,000 communities.
âI am honored and deeply humbled to be marking 25 years of VINE,â said Davis. âThere is no doubt in my mind that every single day there is somebody who is alive because of the work that we do. While nothing can heal the pain of Maryâs loss, we will continue to honor her memory by doing everything we can to equip victims with the information they need to stay safe.â
VINE operates by allowing victims to call a toll-free number, visit www.vinelink.com, or use the VINELink mobile app to anonymously check on an offenderâs custody status. Victims can also register to receive automated notifications about changes in that status via their choice of format: phone, email, or text. TTY (hearing impaired) service is also available. It is offered free of charge to registrants, is completely confidential, and features multiple language support.
What started off as a two-person company working out of Nguyenâs basement, has grown to nearly 1,000 employees across three different business units. United under the corporate mission of Knowledge for Good, Appriss continues to tackle some of the largest societal and business problemsâfrom battling the opioid epidemic, retail fraud, and improper payments in government entitlement agencies, to strengthening law enforcement, community and workplace safety. As Appriss has grown, it has remained rooted in VINE.
âAbove all else: we are victim-centric,â Davis notes. âOur company was built on that foundation. With that as our motivation, our home base, VINE will be around for 100 more years.â
Attachment
2nd Watch Earns 2019 Cloud Services Provider of the Year Award
Channel Partner Insight, a leading channel-focused trade publication, recognizes 2nd Watch for its work helping large enterprises deploy and manage cloud infrastructure
SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- 2nd Watch, a leading professional services and managed cloud services company, has received the Cloud Services Provider of the Year award from Channel Partner Insight (CPI), which provides leaders of resellers, distributors, MSPs and other specialist consultancies with exclusive analysis of the fast-changing channel sector in Europe and the US. 2nd Watch received the award, which recognized the company for its work helping the largest brands adopt and use cloud infrastructure, at CPIâs 2019 Channel Innovation Awards (CIA) ceremony last night in New York City.
The CIAs are for solution providers, distributors and vendors that are galvanizing the channel and advancing new ideas and opportunities. Independently run, the CIAs shine a spotlight on innovation and achievement in the North American channel over the past year. The Cloud Services Provider of the Year award is designed for solution providers that can demonstrate their skill and ability to drive client success. As part of its award application, 2nd Watch detailed its work with AIG, Coca-Cola North America, Covanta, and Crate & Barrel. 2nd Watch was the only winner in the category.
2nd Watch provides an array of cloud-related services, including consulting, assessment, design, migration, security, and management of clientsâ IT infrastructure. 2nd Watch has been recognized by Gartner for the past three years in the Gartner Magic Quadrant for Public Cloud Infrastructure Professional and Managed Service, Worldwide.
âInnovation in the channel is needed now more than ever,â said Josh Budd, editor of Channel Partner Insight. âThe chronic skills gap is widening, yet channel partners are making great strides in enabling customers to modernize their infrastructures and develop smarter, more efficient services. We are excited to recognize 2nd Watchâs contributions as a leading channel player and look forward to monitoring their continued growth and success.â
âWe are honored and excited to accept this award from Channel Partner Insight,â said Jeff Aden, Co-founder and EVP at 2nd Watch. âIt demonstrates our clientsâ successes over the past year, but more broadly our employeesâ ability to innovate and execute over the past decade. As the largest independent cloud service provider, 2nd Watch has firmly established itself as a trusted partner to the largest enterprises and biggest brands on their journey to the cloud. We remain committed to helping these companies transform digitally using cloud infrastructure.â
Source: Gartner, Magic Quadrant for Public Cloud Infrastructure Professional and Managed Services, Worldwide, Craig Lowery, To Chee Eng, et al., 26 February 2019. This report was previously titled Magic Quadrant for Public Cloud Infrastructure Managed Service Providers, Worldwide.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartnerâs research organization and should not be construed as statements of fact. Gartner disclaims all warranties, express or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About 2nd Watch
2nd Watch is an AWS Partner Network Premier Consulting Partner and Microsoft Azure Gold Partner, providing managed cloud services to enterprise clients. The companyâs subject matter experts, software-enabled services and cutting-edge solutions provide companies with tested, proven, and trusted solutions, allowing them to fully leverage the power of the cloud. 2nd Watch solutions are high performing, robust, increase operational excellence, decrease time to market, accelerate growth and lower risk. Its patent-pending, proprietary tools automate everyday workload management processes for big data analytics, digital marketing, line-of-business and cloud native workloads. 2nd Watch is a new breed of business which helps enterprises design, deploy and manage cloud solutions and monitors business critical workloads 24x7. The company is headquartered in Seattle, Washington. To learn more about 2nd Watch, visit www.2ndwatch.com.
###
Media contact:
Kevin Wolf
TGPR
(650) 483-1552
kevin@tgprllc.com
Beter Bed Holding announces sale and lease-back of the distribution centers in Hoogeveen and Nieuw-Vennep
Highlights:
- Beter Beheer B.V., the wholly owned subsidiary of Beter Bed Holding, has entered into two separate sale-and-leaseback transactions for its properties in Hoogeveen and Nieuw-Vennep for a cash consideration of in total ⬠5.1 million. The total book profit on these transactions is circa ⬠1.6 million after tax.
- Together with the previously announced sale-and-leaseback transaction of the property in Uden (Linie 27), these transactions show that the Benelux operations of Beter Bed Holding will continue operating in its current logistical structure.
- These transactions contribute to the improvement of the net debt position of Beter Bed Holding, because the proceeds will be used to repay bank debt. Together with the divestment of Matratzen Concord that was completed on 2 December, these transactions are important steps for the transformation of Beter Bed Holding.
John Kruijssen, CEO of Beter Bed Holding, comments:
âWith these sale-and-leaseback transactions and the divestment of Matratzen Concord we completed major milestones that were identified to turnaround Beter Bed Holding. Especially after the divestment of Matratzen Concord, Beter Bed Holding transformed into a flexible company that is a market leader in the Benelux. As a result of the completed transactions, the net debt level of Beter Bed Holding substantially improved. This will enable us to further accelerate the growth of the continuing operations. As previously announced, we will organise a Capital Markets Day to present our refined strategy and ambitions for the transformed company in April 2020.â
Beter Bed Holding was advised by Colliers International and De Brauw Blackstone Westbroek.
Profile
Beter Bed Holding is a European retail organisation that offers its customers the best quality rest at affordable prices. The organisationâs aim is to do this through its international retail brands, through its own wholesaler operation DBC International and, at an increasingly relevant share, through Digital channels.
For more information
John Kruijssen                                                                  Hugo van den Ochtend  Â
CEOÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CFOÂ Â Â Â Â Â Â
+31 (0)413 338819Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â +31 (0)413 338819Â Â Â Â Â Â Â Â Â Â Â
+31 (0)6 13211011Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â +31 (0)6 25746309Â Â Â Â Â Â Â Â Â Â Â
john.kruijssen@beterbed.nl                                                hugo.vandenochtend@beterbed.nl          Â
Â
Please click on the link below for the PDF of the press release. Press photos can be downloaded here.
Â
Attachment
VILNIAUS BALDAI AB investor's calendar for 2020FY
VILNIAUS BALDAI AB plans to release financial results in Financial Year 2020 (starting September 1, 2019 and ending August 31, 2020) according to the following plan:
- December 23, 2019 â consolidated interim financial statements for the three months;
- April 03, 2020 â consolidated interim financial statements for the six months; consolidated interim report for the six months;
- June 26, 2020 â consolidated interim financial statements for the nine months;
- October 23, 2020 â consolidated interim financial statements for the twelve months;
- November 23, 2020 â consolidated annual financial statements; consolidated annual report.
Additional information:
Chief Financial Officer
Edgaras KabeÄius
Phone No.: +370 (5) 2525700
Share Buy-back programme at SP Group A/S
On 11 April 2019, SP Group initiated a share buy-back programme, cf. company announcement no. 14/2019 of 27 March 2019. The share buy-back programme was extended on 29 April 2019 by DKK 15 million to DKK 55 million (company announcement no. 29/2019). The share buy-back programme has been increased and extended according to company announcement no. 45/2019 of 22 August 2019. According to the programme, SP Group will in the period from 11 April 2019 until 10 April 2020 purchase own shares for a maximum amount of DKK 95.0 million.
The share buy-back programme was initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014 about Market Abuse, the so-called Market Abuse Regulation that protects listed companiesâ board and executive board against violation of insider legislation in connection with share buy-backs.
Attachment
